Emesis- Pipeline Insight, 2024

Emesis- Pipeline Insight, 2024

DelveInsight’s, “Emesis- Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Emesis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Emesis: Understanding

Emesis: Overview

Vomiting is rarely painful, but never pleasant. Vomiting, also known scientifically as “emesis” and colloquially as throwing up, retching, heaving, hurling, puking, tossing, or being sick, is the forcible voluntary or involuntary emptying of stomach contents through the mouth or, less often, the nose. Vomiting is the body’s way of ridding itself of harmful substances from the stomach, or it may be a reaction to something that has irritated the gut. There are different types of vomiting. Some people get the dry heaves, where person retches and feels like vomiting, but nothing comes out of stomach. The dry heaves are also called nonproductive emesis. Blood streaked or bloody vomit usually indicates a cut or scrape to the esophagus or stomach. Some vomit resembles coffee grounds. Vomit that looks like coffee grounds occurs when stomach acids and blood congeal. Coffee ground vomit can be a sign of ulcer, gastroesophageal reflux disease (GERD), cancer of the stomach or liver, or other abdominal conditions. Yellow vomit indicates the presence of bile, which usually happens after a meal. It’s rare, but people with abnormal intestinal function could possibly vomit up partially digested food or feces. Vomiting is common. Eating too much food or drinking too much alcohol can make a person throw up. This generally isn’t a cause for concern. Vomiting itself is not a condition. It’s a symptom of other conditions. Some of these conditions include: food poisoning, indigestion, infections (associated with bacterial and viral illnesses), motion sickness, pregnancy-related morning sickness, headaches, prescription medications, anesthesia and chemotherapy. Frequent vomiting not related to any of the above mentioned causes may be a symptom of cyclic vomiting syndrome. This condition is characterized by vomiting for up to 10 days. It is usually coupled with nausea and extreme lack of energy. It mainly occurs during childhood. Diagnostic testing for nausea and vomiting should be targeted at finding the etiology suggested by a thorough history and physical examination. Fluid imbalances, electrolyte abnormalities, and nutritional deficiencies should be corrected.

""Emesis- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Emesis pipeline landscape is provided which includes the disease overview and Emesis treatment guidelines. The assessment part of the report embraces, in depth Emesis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Emesis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Emesis R&D. The therapies under development are focused on novel approaches to treat/improve Emesis.

Emesis Emerging Drugs Chapters

This segment of the Emesis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Emesis Emerging Drugs

• Staccato granisetron: Alexza Pharmaceuticals

Staccato granisetron, is a small molecule being developed by Alexza Pharmaceuticals. The drug works as a serotonin 3 receptor antagonists. Currently, the drug is in Phase II stage of Clinical trial evaluation for the acute treatment of cyclic vomiting syndrome.

• TAK 951: Takeda

TAK-951 is being tested for prophylaxis for postoperative nausea and vomiting in high-risk participants. TAK 951 belongs to the class of antiemetics.This drug basically works as peptide modulators. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Postoperative Nausea and Vomiting (PONV).

• STAR-OLZ : Starton Therapeutics

STAR-OLZ is a 5-day transdermal patch in development for the treatment of chemotherapy induced nausea and vomiting (CINV).STAR-OLZ successfully completed Phase I human bioavailability studies and is now preparing to advance to a Phase II clinical trial.

Further product details are provided in the report……..

Emesis: Therapeutic Assessment

This segment of the report provides insights about the different Emesis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Emesis

There are approx. 10+ key companies which are developing the therapies for Emesis. The companies which have their Emesis drug candidates in the most advanced stage, i.e. phase II include, Takeda.

Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Emesis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Emesis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Emesis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Emesis drugs.

Emesis Report Insights

• Emesis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Emesis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Emesis drugs?
• How many Emesis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Emesis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Emesis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Emesis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Takeda
• Starton Therapeutics
• Alexza Pharmaceuticals
• Repurposed Therapeutics
• Benuvia Therapeutics
• Aphios Corporation
• Sentia Medical Sciences

Key Products

• DPI-386
• STAR-OLZ
• TAK 951
• Staccato granisetron
• Zindol
• Research programme: astressins